Anju Ghangurde
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Anju Ghangurde
AstraZeneca Bolstering India Play With $90m Investment Plan
AstraZeneca expects to invest $90m over five years to shore up its footprint in India – a market where the Anglo-Swedish major has introduced a string of new products but has also had a fair share of challenges.
Pfizer Seeks To Block Infringement Of Sutent Patent In India
Eisai Primes Push For Biogen MS Range In India
Eisai is straddling a mix of new opportunities for growth in India as it takes charge of sales of Biogen’s multiple sclerosis portfolio in the country and also eyes potential gains from its Japanese parent’s recent deal with Nichi-Iko.
Mylan Looks To Expedite Biosimilar Humira in EU Through Kyowa Deal
Can Pharmas Come Out Unscathed As China-US Trade War Escalates?
As a simmering trade dispute between the US and China looks set to continue worsening, many companies in the pharma sector are closely watching what's coming and getting ready for any disruption. But what is the actual and predicted impact on exporters and producers in China, India and the US?
Can Pharmas Come Out Unscathed As China-US Trade War Escalates?
As a simmering trade dispute between the US and China looks set to continue worsening, many companies in the pharma sector are closely watching what's coming and getting ready for any disruption. But what is the actual and predicted impact on exporters and producers in China, India and the US?